Welcome to our dedicated page for Affimed SEC filings (Ticker: AFMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Affimed N.V. filings document a corporate-status transition for the clinical-stage immuno-oncology issuer. The recent SEC record centers on Form 25, filed by Nasdaq, covering removal of the company’s common stock from listing and registration under Section 12(b) of the Securities Exchange Act. These disclosures establish the formal exchange-listing and registration record associated with Affimed’s delisting from Nasdaq.
Nasdaq Stock Market LLC has filed Form 25 to strike Affimed N.V. (AFMD) common stock from listing and registration under Section 12(b) of the Exchange Act. The notification, signed on 2025-07-21 by a Nasdaq hearings advisor, states that the exchange believes it meets all regulatory requirements for delisting. No financial results, trading data, or rationale are provided in the filing.
The action will remove AFMD from the Nasdaq Global Market once the SEC’s 10-day period elapses, and registration under Section 12(g) will be terminated after 90 days unless the company files contrary documentation. Investors should anticipate the stock moving to an over-the-counter venue or another exchange, subject to separate listing standards.